$33.36
0.170.51%
Últ. Act.: Oct 23, 1:58 PM
Castle Biosciences (CSTL) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Castle Biosciences (CSTL) publicó su última previsión de julio 30, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $365M - $375M para el período.
En comparación con la previsión anterior, Castle Biosciences elevado redujo su previsión de ingresos desde un rango anterior de $345M - $355M.
Castle Biosciences ha emitido 16 actualizaciones de orientación entre el noviembre 2, 2022 y el julio 30, 2026. During this period, the company raised its outlook 11 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.41 | $-0.50 | $-0.24 | $-0.44 |
| Actual | $-0.07 | $-0.49 | $-0.08 | $-0.02 |
| Surprise | +82.9% | +2.00% | +66.7% | +95.5% |
| Revenue | ||||
| Estimate | $86.6M | $79.7M | $80.3M | $71.2M |
| Actual | $103.5M | $83.7M | $87.0M | $83.0M |
| Surprise | +19.6% | +5.03% | +8.34% | +16.6% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.36 | $-0.36 | $-0.40 | $-0.25 |
| Revenue | ||||
| Consensus | $92.4M | $94.3M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $-0.07 | $-0.41 | 82.9 % |
| Q1 | May 6, 2026 | $-0.49 | $-0.50 | 2.00 % |
| Q4 | Feb 26, 2026 | $-0.08 | $-0.24 | 66.7 % |
| Q3 | Nov 3, 2025 | $-0.02 | $-0.44 | 95.5 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $103.55M | $86.56M | 19.6 % |
| Q1 | May 6, 2026 | $83.70M | $79.69M | 5.03 % |
| Q4 | Feb 26, 2026 | $87.01M | $80.31M | 8.34 % |
| Q3 | Nov 3, 2025 | $83.04M | $71.20M | 16.6 % |